Dr Reddys Laboratories Q3 Results 2025 on 25 Jan, 2025: profit rise by 2.38% YOY, profit at ₹1413.7 crore and revenue at ₹8381.2 crore | Company Business News
Dr Reddys Laboratories Q3 Results 2025:Dr Reddys Laboratories declared their Q3 results on 23 Jan, 2025, showcasing a topline increase of 15.81% YoY. The profit rose by 2.38% YoY, with profit figures reaching ₹1413.7 crore and revenue hitting ₹8381.2 crore.
Compared to the previous quarter, revenue grew by 4.27% while profit increased by 12.58%. However, the Selling, General & Administrative expenses saw a rise of 0.7% quarter-on-quarter and 16.53% year-on-year.
The operating income for the quarter was up by 7.27% on a quarter-on-quarter basis and increased by 9.21% year-on-year. The Earnings Per Share (EPS) stood at ₹16.94 for Q3, marking an increase of 1.68% YoY.
Dr Reddys Laboratories has reported a -1.02% return in the last week, a -5.93% return over the last six months, and a -7.14% year-to-date return.
Currently, Dr Reddys Laboratories has a market capitalization of ₹107422.6 crore, with a 52-week high of ₹1421.49 and a low of ₹1120.
As of 25 Jan, 2025, out of 35 analysts covering the company, 5 have issued a Strong Sell rating, 8 a Sell rating, 9 a Hold rating, 7 a Buy rating, and 6 a Strong Buy rating. The consensus recommendation as of this date was to Hold.
Dr Reddys Laboratories Financials
| Period | Q3 (FY25) | Q2 (FY25) | Q-o-Q Growth | Q3 (FY24) | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 8381.2 | 8038.2 | +4.27% | 7236.8 | +15.81% |
| Selling/ General/ Admin Expenses Total | 3527.1 | 3502.6 | +0.7% | 3026.7 | +16.53% |
| Depreciation/ Amortization | 471.4 | 397 | +18.74% | 373.5 | +26.21% |
| Total Operating Expense | 6579.6 | 6358.7 | +3.47% | 5587.2 | +17.76% |
| Operating Income | 1801.6 | 1679.5 | +7.27% | 1649.6 | +9.21% |
| Net Income Before Taxes | 1874.3 | 1917.4 | -2.25% | 1829.1 | +2.47% |
| Net Income | 1413.7 | 1255.7 | +12.58% | 1380.9 | +2.38% |
| Diluted Normalized EPS | 16.94 | 15.85 | +6.88% | 16.66 | +1.68% |
Disclaimer: This is an AI-generated live blog and has not been edited by LiveMint staff.
